Laboratory monitoring of heparin therapy: Partial thromboplastin time or anti-Xa assay?

Laboratory Medicine

Volumn 40, Issue 1, 2009, Pages 47-51

  Lehman, Christopher M ^a   Frank, Elizabeth L ^a  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ASSAY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG ELIMINATION; DRUG MECHANISM; DRUG SUBSTITUTION; HEPARINIZATION; HUMAN; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; REVIEW; THROMBOEMBOLISM; TREATMENT INDICATION; VALIDITY;

EID: 77952004518     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LM9NJGW2ZIOLPHY6     Document Type: Review

References (16)

1. Valenstein PN, Walsh MK, Meier F. Heparin monitoring and patient safety: A College of American Pathologists Q-Probes study of 3431 patients at 140 institutions. Arch Pathol Lab Med. 2004;128:397-402.
2. Bennett ST. Monitoring Anticoagulant Therapy. In: Bennett ST, Lehman CM, Rodgers GM, eds. Laboratory Hemostasis: A Practical Guide for Pathologists, 1st ed. New York: Springer; 2007: 167-205.
3. Hirsh J, Anand SS, Halperin JL, et al. AHA Scientific Statement: Guide to Anticoagulant therapy: A statement for healthcare professionals from the American Heart Association. Arterioscler Thromb Vasc Biol. 2001;21:E9.
4. Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: A systematic review for a practice guideline. Ann Intern Med. 2007;146:211-222.
5. Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Eng J Med. 1972;287:324-327.
6. Chiu HM, Hirsh J, Yung WL, et al. Relationship between the anticoagulant and thrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184. (Pubitemid 8032549)
7. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost. 2006;96:547-552.
8. Hirsh J, Bates S. The multiple faces of the partial thromboplastin time APTT. J Thromb Haemost. 2004;2:2254-2256.
9. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56. (Pubitemid 24018101)
10. Kitchen S, Preston FE. The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost. 1996;75:734-739.
11. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122:782-798. (Pubitemid 28411236)
12. Smythe MA, Mattson JC, Koerber JM. The heparin anti-Xa therapeutic range: Are we there yet? Chest. 2002;122:303-304.
13. College of American Pathologists 2007 Hematology and Coagulation Laboratory Accreditation Checklist. www.cap.org.
14. Kearon C, Johnston M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med. 1998;158:1140-1143.
15. Lehman CM, Rettmann JA, Wilson LW, et al. Comparative performance of three anti-Factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol. 2006;126:416-421.
16. Winkler AM, Sheppard CA, Fantz CR, et al. Laboratory monitoring of heparin: Challenges and opportunities. Lab Med. 2007; 38:499-502. (Pubitemid 47206332)